Cargando…
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671469/ https://www.ncbi.nlm.nih.gov/pubmed/38003302 http://dx.doi.org/10.3390/ijms242216109 |
_version_ | 1785140164219109376 |
---|---|
author | Fahey, Catherine C. Nebhan, Caroline A. York, Sally Davis, Nancy B. Hurley, Paula J. Gordetsky, Jennifer B. Schaffer, Kerry R. |
author_facet | Fahey, Catherine C. Nebhan, Caroline A. York, Sally Davis, Nancy B. Hurley, Paula J. Gordetsky, Jennifer B. Schaffer, Kerry R. |
author_sort | Fahey, Catherine C. |
collection | PubMed |
description | Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients. |
format | Online Article Text |
id | pubmed-10671469 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106714692023-11-09 Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin Fahey, Catherine C. Nebhan, Caroline A. York, Sally Davis, Nancy B. Hurley, Paula J. Gordetsky, Jennifer B. Schaffer, Kerry R. Int J Mol Sci Case Report Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody–drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients. MDPI 2023-11-09 /pmc/articles/PMC10671469/ /pubmed/38003302 http://dx.doi.org/10.3390/ijms242216109 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Fahey, Catherine C. Nebhan, Caroline A. York, Sally Davis, Nancy B. Hurley, Paula J. Gordetsky, Jennifer B. Schaffer, Kerry R. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
title | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
title_full | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
title_fullStr | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
title_full_unstemmed | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
title_short | Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin |
title_sort | metastatic penile squamous cell carcinoma responsive to enfortumab vedotin |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671469/ https://www.ncbi.nlm.nih.gov/pubmed/38003302 http://dx.doi.org/10.3390/ijms242216109 |
work_keys_str_mv | AT faheycatherinec metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT nebhancarolinea metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT yorksally metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT davisnancyb metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT hurleypaulaj metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT gordetskyjenniferb metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin AT schafferkerryr metastaticpenilesquamouscellcarcinomaresponsivetoenfortumabvedotin |